Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of lithium sodium 5-amino-3-{[4-(2-{4-[(7-amino-1-hydroxy-3-sulfo-2-naphthyl)diazenyl]-2-sulfophenyl}vinyl)-3-sulfophenyl]diazenyl}-4-hydroxynaphthalene-2,7-disulfonate 2,2'-(methylimino)diethanol (1:1) and 3,3'-[vinylenebis[(3-sulpho-p-phenylene)azo]]bis[6-amino-4-hydroxynaphthalene-2-sulphonic] acid, lithium sodium salt, compound with 2,2'-(methylimino)diethanol and 3,3'-[vinylenebis[(3-sulpho-p-phenylene)azo]]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonic] acid, lithium sodium salt, compound with 2,2'-(methylimino)diethanol
EC number: 916-916-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Bayscript Blaukomponente proved to be non-mutagenic in the Ames test, the HPRT-test and in the MNT in vitro. All three tests were performed according to the respective guidelines and GLP conditions and evaluated with Klimisch score 1.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Additional strain / cell type characteristics:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix was made from the livers of at least 5 adult male Sprague-Dawley rats . For enzyme induction the animals received a single intraperitoneal injection of Aroclor 1254 dissolved in corn oil five days prior to sacrifice
- Test concentrations with justification for top dose:
- with and without S9-mix:
50, 160, 500, 1600, 5000 µg/plate - Vehicle / solvent:
- deionized water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- sodium azide
- cumene hydroperoxide
- mitomycin C
- other: 4-nitro-1,2-phenylend diamine; 2-aminoanthracene
- Details on test system and experimental conditions:
- 2 independent trials :
according to preincubation methodology or according to plate incorporation methodology - Evaluation criteria:
- A reproducible and dose-related increase in mutant counts of at least one strain is considered to be a positive result. For TA1535, TA100, TA1537, TA98 this increase should be about twice that of negative controls. For TA102 an increase of about 100 mutants should be reached.
Otherwise the result is evaluated as negative - Statistics:
- no data
- Key result
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- Interpretation of results: negative
According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified. - Executive summary:
Bayscript Blaukomponente was initially investigated in the Ames test according to OECD TG 471 and GLP using the Salmonella typhimurium TA 98, TA100, TA102, TA1535, TA1537 and concentrations up to and including 5000 µg/plate. Bacteriotoxicity was not reached. None of the 5 strains used showed a dose-related and biologically relevant increase in mutant counts over those of the negative controls neither in the presence nor in the absence of the metabolic activation system S9 -mix. The positive controls were functional. Therefore, Bayscript Blaukomponente was considered to be non--mutagenic without and with S9 -mix in the plate incorporation as well as in the preincubation modification of the Salmonella /microsome test.
- Endpoint:
- in vitro cytogenicity / micronucleus study
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: OECD TG 487, 2010
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian cell micronucleus test
- Target gene:
- chromosome aberration test
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Additional strain / cell type characteristics:
- other: Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Metabolic activation system:
- liver homogenate (S9: 9000 x g fraction) from livers of Aroclor 1254-induced male Sprague-Dawley rats
- Test concentrations with justification for top dose:
- 4 hour-treatment:
with S9-mix: and without S9-mix:
250, 500, 1000, 2000, 3000, 4000, 5000 µg/ml
24 hour-treatment:
without S9-mix:
25, 50, 100, 250, 500, 1000, 2000 µg/ml - Vehicle / solvent:
- deionized water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- N-ethyl-N-nitro-N-nitrosoguanidine
- cyclophosphamide
- mitomycin C
- other: 4 hour treatment, with S9-mix Cyclophosphamide; without S9-mix: Mitomycin C; Vinblastine sulfate salt
- Details on test system and experimental conditions:
- In this study, two independent assays were performed, the first assay conducted with a treatment time of 4 hours (pulse treatment), consisting of one experiment in the absence and one experiment in the presence of an extrinsic metabolizing system (S9 mix). In the second assay, an experiment without S9 mix was performed with treatment time extended to 24 hours (continuous treatment).
- Evaluation criteria:
- The test item is classified as mutagenic if one of the test substance concentrations induces a micronucleus frequency that is three times higher than the micronucleus frequency of the negative control
- Statistics:
- no statistical methods available
- Key result
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 4 hour treatment, with S9-mix: 500 µg/ml and above; 4-hour treatment, without S9-Mix: 1000 µg/ml and above; 24 hour treatment, without S9-mix: 25 µg/ml and above
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- Interpretation of results: negative
According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified. - Executive summary:
Bayscript Blaukomponente was examined for mutagenic activity in the micronucleus test in vitro according to OECD TG 487 in the presence and in th absence of a metabolic activation system..Cytotoxic effects were observed.(4 hour treatment, with S9-mix: 500 µg/ml and above; 4-hour treatment, without S9-Mix: 1000 µg/ml and above; 24 hour treatment, without S9-mix: 25 µg/ml and above) No precipitation was observed . No biologically relevant increase in the frequencies of micronucleus containing V79 cells treated with the test item in the absence (4 hours or 24 hours treatment) or in the presence of S9 mix.were seen.
Evaluation of the data does not indicate that Bayscript Blaukomponente is a mutagen in the micronucleus test in vitro in the absence or presence of metabolic activation.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- GLP compliance:
- yes
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- HPRT locus
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Additional strain / cell type characteristics:
- other: The cells have a stable karyotype with a modal chromosome number of 22
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix was prepared from 8-12 weeks old male Wistar rats induced by intraperitoneal applications of phenobarbital and peroral application of ß-naphthoflavone on 3 consecutive days
- Test concentrations with justification for top dose:
- EXPERIMENT I
without S9-mix (4 hour treatment):
887.5, 1775, 3559, 7100, 10650, 14200 µg/ml
with S9-mix(4 hour treatment)
443.8, 887.5, 1775, 3550, 7100, 10650 µg/ml
EXPERIMENT II
without S9-mix (24 hour treatment)
443.8, 887.5, 1775, 3550, 7100, 10650 µg/ml
with S9-mix (4 hour treatment)
443.8, 887.5, 1775, 3550, 7100, 10650 µg/ml - Vehicle / solvent:
- deionised water
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- not specified
- Positive controls:
- yes
- Positive control substance:
- other: Without metabolic activation: EMS; ethylmethane sulfonate; With metabolic activation: DMBA; 7,12-dimethylbenz(a)anthracene
- Details on test system and experimental conditions:
- the assay was performed in 2 independent experiments, using 2 parallel cultures each. The first main experiment was performed with and without liver microsomal activation and a treatment period of 4 hours. The second experiment was performed with a treatment time of 4 hours with and 24 hours without metabolic activation
- Evaluation criteria:
- A test item is classified as positive if it induces either a concentration-related increase of the mutant frequency or a reproducible and positive response at one of the test points.
A test item producing neither a concentration-related increase of the mutant frequency nor a reproducible positive response at any of the test points is considered non-mutagenic in this system. - Statistics:
- A linear regression (least squares) was performed to assess a possible dose dependent increase of mutant frequencies. The number of mutant colonies obtained for the groups treated with the test item were compared to the solvent control groups. A trend is judged as significant whenever the p-value (probability value) is below 0.05.
- Key result
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Experiment I without S9-mix: at 10650 µg/ml and above; with S9-mix: at 7100 µg/ml and above; in experiment II at 7100 µg/ml and above with and without S9-mix
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- Interpretation of results: negative
According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified. - Executive summary:
The study was performed to investigate the potential of Bayscript Blaukomponente to induce gene mutations at the HPRT locus in V79 cells of the Chinese hamster according to OECD TG 476. The assay was performed in two independent experiments, using two parallel cultures each. The first main experiment was performed with and without liver microsomal activation and a treatment period of 4 hours. The second experiment was performed with a treatment time of 4 hours with and 24 hours without metabolic activation. No precipitation of the test item at the end of treatment was noted. Cytotoxicity was observed in experiment I without S9-mix: at 10650 µg/ml and above; with S9-mix: at 7100 µg/ml and above; in experiment II at 7100 µg/ml and above with and without S9-mix
No substantial and reproducible dose dependent increase of the mutation frequency was observed in both main experiments.
Appropriate reference mutagens, used as positive controls, induced a distinct increase in mutant colonies and thus, showed the sensitivity of the test system and the activity of the metabolic activation system.
In conclusion it can be stated that under the experimental conditions reported, the test item did not induce gene mutations at the HPRT locus in V79 cells. Therefore, Byscript Blaukomponente is considered to be non-mutagenic in this HPRT assay.
Referenceopen allclose all
No substantial and reproducible dose dependent increase of the mutation frequency was observed in both main experiments.
Appropriate reference mutagens, used as positive controls, induced a distinct increase in mutant colonies and thus, showed the sensitivity of the test system and the activity of the metabolic activation system.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Ames test
Bayscript Blaukomponente was initially investigated in the Ames test according to OECD TG 471 and GLP using the Salmonella typhimurium TA 98, TA100, TA102, TA1535, TA1537 and concentrations up to and including 5000 µg/plate. Bacteriotoxicity was not reached. None of the 5 strains used showed a dose-related and biologically relevant increase in mutant counts over those of the negative controls either in the presence nor in the absence of the metabolic activation system S9-mix. The positive controls were functional.
Due to these results Bayscript Blaukomponente has to be regarded as non-mutagenic in this Ames test.
HPRT test
The study was performed to investigate the potential of Bayscript Blaukomponente to induce gene mutations at the HPRT locus in V79 cells of the Chinese hamster according to OECD TG 476. The assay was performed in two independent experiments, using two parallel cultures each. The first main experiment was performed with and without liver microsomal activation and a treatment period of 4 hours. The second experiment was performed with a treatment time of 4 hours with and 24 hours without metabolic activation. No precipitation of the test item at the end of treatment was noted. Cytotoxicity was observed in experiment I without S9-mix: at 10650 µg/ml and above; with S9-mix: at 7100 µg/ml and above; in experiment II at 7100 µg/ml and above with and without S9-mix
No substantial and reproducible dose dependent increase of the mutation frequency was observed in both main experiments.
Appropriate reference mutagens, used as positive controls, induced a distinct increase in mutant colonies and thus, showed the sensitivity of the test system and the activity of the metabolic activation system.
In conclusion it can be stated that under the experimental conditions reported, the test item did not induce gene mutations at the HPRT locus in V79 cells. Therefore, Bayscript Blaukomponente is considered to be non-mutagenic in this HPRT assay.
MNT in vitro
Bayscript Blaukomponente was examined for mutagenic activity in the micronucleus test in vitro according to OECD TG 487 in the presence and in the absence of a metabolic activation system. Cytotoxic effects were observed (4 hour treatment, with S9-mix: 500 µg/ml and above; 4-hour treatment, without S9-Mix: 1000 µg/ml and above; 24 hour treatment, without S9-mix: 25 µg/ml and above). No precipitation was observed. No biologically relevant increase in the frequencies of micronucleus containing V79 cells treated with the test item in the absence (4 hours or 24 hours treatment) or in the presence of S9 mix were seen.
Evaluation of the data does not indicate that Bayscript Blaukomponente is a mutagen in the micronucleus test in vitro in the absence or presence of metabolic activation.
Justification for selection of genetic toxicity endpoint
No endpoint was selected because Bayscript Blaukomponente proved to
be non-mutagenic in the Ames test, the HPRT-test and in the MNT in
vitro. All
three tests were performed according to the respective guideines and GLP
conditions and evaluated with Klimisch score 1
Short description of key information:
Bayscript Blaukomponente proved to be non-mutagenic in the Ames
test, the HPRT-test and in the MNT in vitro. All three tests were
performed according to the respective guideines and GLP conditions and
evaluated with Klimisch score 1
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Bayscript Blaukomponente was negative in the Ames test, the HPRT-test and in the MNT in vitro. All three tests were performed according to the respective guidelines and GLP conditions and evaluated with Klimisch score 1. According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.